Profile data is unavailable for this security.
About the company
Azitra, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing advanced therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. It has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its lead product, ATR-12, is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its advanced product, ATR-04, is a genetically modified strain of S. epidermidis for treating papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.
- Revenue in USD (TTM)0.00
- Net income in USD-11.12m
- Incorporated2014
- Employees12.00
- LocationAzitra Inc21 Business Park Drive, Suite 6BRANFORD 06405United StatesUSA
- Phone+1 (203) 489-0183
- Fax+1 (302) 655-5049
- Websitehttps://azitrainc.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CDT Equity Inc | 0.00 | -20.70m | 1.92m | 6.00 | -- | 0.3103 | -- | -- | -473.79 | -473.79 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -358.56 | -- | -- | -- | -- | -- | -- | -- | -- | -16.00 | 0.2881 | -- | -- | -- | -3,227.48 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -20.07m | 1.93m | 7.00 | -- | 0.3018 | -- | -- | -134.42 | -134.42 | 0.00 | 9.01 | 0.00 | -- | -- | 0.00 | -103.46 | -70.71 | -124.04 | -82.92 | -- | -- | -- | -12,694.84 | -- | -- | 0.0028 | -- | -- | -- | -110.38 | -- | 119.51 | -- |
| Yubo International Biotech Ltd | -20.00 | -1.23m | 1.96m | 18.00 | -- | -- | -- | -- | -0.0099 | -0.0099 | 0.00 | -0.0098 | -0.00002 | -0.0005 | -- | -1.11 | -105.87 | -- | -- | -- | -- | -- | -- | -- | 0.2394 | -- | -- | -- | -99.43 | -- | -48.55 | -- | -- | -- |
| Zyversa Therapeutics Inc | 0.00 | -25.70m | 2.02m | 7.00 | -- | -- | -- | -- | -4.46 | -4.46 | 0.00 | -1.45 | 0.00 | -- | -- | 0.00 | -251.13 | -- | -- | -- | -- | -- | -- | -- | -- | -14.60 | -- | -- | -- | -- | 91.14 | -- | -- | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 2.11m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.18m | 11.00 | -- | 0.8931 | -- | 5.68 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| Bone Biologics Corp | 0.00 | -3.95m | 2.19m | 2.00 | -- | 0.364 | -- | -- | -7.30 | -7.30 | 0.00 | 3.35 | 0.00 | -- | -- | 0.00 | -75.76 | -86.22 | -80.46 | -561.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.15 | -- | -- | -- |
| Azitra Inc | 0.00 | -11.12m | 2.22m | 12.00 | -- | 0.5088 | -- | -- | -5.49 | -5.49 | 0.00 | 0.4066 | 0.00 | -- | -- | 0.00 | -157.91 | -- | -203.88 | -- | -- | -- | -- | -- | -- | -- | 0.1197 | -- | -98.91 | -- | 29.05 | -- | -- | -- |
| Hcw Biologics Inc | 422.03k | -22.21m | 2.23m | 36.00 | -- | -- | -- | 5.28 | -13.96 | -13.96 | 0.2716 | -0.8038 | 0.0162 | -- | 1.24 | 11,723.06 | -46.35 | -53.89 | -- | -66.10 | 20.00 | -- | -2,855.77 | -545.79 | -- | -42.26 | 1.45 | -- | -9.68 | -- | -20.12 | -- | -29.10 | -- |
| ABPRO Holdings Inc | 0.00 | -22.04m | 2.25m | 6.00 | -- | -- | -- | -- | -24.37 | -24.37 | 0.00 | -6.04 | 0.00 | -- | -- | 0.00 | -467.23 | -- | -- | -- | -- | -- | -- | -- | -- | -4.82 | -- | -- | 50.00 | -- | -48.72 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 2.26m | 21.00 | -- | -- | -- | 20.14 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| CNS Pharmaceuticals Inc | 0.00 | -13.07m | 2.30m | 4.00 | -- | 0.2145 | -- | -- | -130.83 | -130.83 | 0.00 | 17.25 | 0.00 | -- | -- | 0.00 | -135.60 | -153.00 | -197.11 | -237.57 | -- | -- | -- | -- | -- | -- | 0.0031 | -- | -- | -- | 21.18 | -- | -26.93 | -- |
| Lyra Therapeutics Inc | 600.00k | -32.95m | 2.34m | 30.00 | -- | -- | -- | 3.90 | -23.78 | -23.78 | 0.418 | -2.63 | 0.0098 | -- | -- | 20,000.00 | -53.81 | -64.59 | -67.22 | -76.36 | -- | -- | -5,491.17 | -5,844.58 | -- | -- | -- | -- | -1.54 | -- | -49.07 | -- | 61.78 | -- |
| Cardio Diagnostics Holdings Inc | 15.79k | -6.55m | 2.36m | 13.00 | -- | 0.2796 | -- | 149.18 | -4.07 | -4.07 | 0.0097 | 4.61 | 0.0024 | -- | 1.25 | 1,214.62 | -98.75 | -- | -104.31 | -- | -- | -- | -41,495.31 | -- | -- | -440.22 | 0.00 | -- | 104.39 | -- | -0.079 | -- | -- | -- |
| InMed Pharmaceuticals Inc | 4.80m | -8.21m | 2.60m | 13.00 | -- | 0.20 | -- | 0.5415 | -7.21 | -7.21 | 2.65 | 4.45 | 0.4028 | 3.01 | 15.28 | -- | -68.93 | -87.37 | -78.82 | -107.49 | 33.69 | -- | -171.13 | -356.16 | 6.37 | -27.94 | 0.00 | -- | 7.50 | -- | -6.34 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Azitra Inc's reporting currency: US Dollar USD
10.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alumni Capital Management LLCas of 02 Jan 2026 | 1.13m | 10.55% |
| Geode Capital Management LLCas of 30 Sep 2025 | 21.76k | 0.20% |
| National Bank Financial, Inc.as of 30 Sep 2025 | 19.52k | 0.18% |
| UBS Securities LLCas of 31 Dec 2025 | 998.00 | 0.01% |
| Tower Research Capital LLCas of 30 Sep 2025 | 103.00 | 0.00% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 40.00 | 0.00% |
| BofA Securities, Inc.as of 30 Sep 2025 | 0.00 | 0.00% |
| L1 Capital Global, Inc.as of 14 Nov 2025 | 0.00 | 0.00% |
| HRT Financial LPas of 30 Sep 2025 | 0.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 15 Jan 2026Source: FactSet Research Systems Inc.
